Cardiovascular disease prevention with a multidrug regimen in the developing world: a cost-effectiveness analysis

Background Cardiovascular disease is the leading cause of death, with 80% of cases occurring in developing countries. We therefore aimed to establish whether use of evidence-based multidrug regimens for patients at high risk for cardiovascular disease wou